Ropeginterferon alfa-2b, sold under the brand name Besremi, is a medication used to treat polycythemia vera. It is an interferon. It is given by injection.The most common side effects include low levels of white blood cells and platelets (blood components that help the blood to clot), muscle and joint pain, tiredness, flu-like symptoms and increased blood levels of gamma-glutamyl transferase (a sign of liver problems). Ropeginterferon alfa-2b can cause liver enzyme elevations, low levels of white blood cells, low levels of platelets, joint pain, fatigue, itching, upper airway infection, muscle pain and flu-like illness. Side effects may also include urinary tract infection, depression and transient ischemic attacks (stroke-like attacks).It was approved for medical use in the European Union in February 2019, and in the United States in November 2021. Ropeginterferon alfa-2b is the first medication approved by the U.S. Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera. Medical uses
In the European Union, ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythemia vera without symptomatic splenomegaly. In the United States it is indicated for the treatment of polycythemia vera. History
The effectiveness and safety of ropeginterferon alfa-2b were evaluated in a multicenter, single-arm trial that lasted 7.5 years. In this trial, 51 adults with polycythemia vera received ropeginterferon alfa-2b for an average of about five years.
Diagnosis
The diagnosis for argininemia can usually be done using fetal blood sample. One can look for the following indicators as to the presence of the condition:
Plasma ammonia concentration. Urinary orotic acid concentration
Red blood cell arginase enzyme activity (measurement)

Treatment
The treatment for infants (individuals) with argininemia is the following, including medications:

References
Further reading
(editors), Jean-Marie Saudubray, Georges van den Berghe, John H. Walter; Berghe, Georges van den; Walter, John H. (2012). Inborn metabolic diseases diagnosis and treatment (5th ed.). Berlin: Springer. ISBN 9783642157202. Retrieved 28 November 2016. {{cite book}}: |last1= has generic name (help)
Piña-Garza, J. Eric (2013). Fenichels Clinical pediatric neurology a signs and symptoms approach (7th ed.). Oxford: Saunders. ISBN 978-1455748129. Retrieved 28 November 2016. == External links ==